A 52-Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24-Week Open-Label Follow-Up to Evaluate the Effect of Avandia on Bone in Postmenopausal Women With Type 2 Diabetes Mellitus.

Trial Profile

A 52-Week Randomized, Double-Blind, Multicenter, Mechanistic Study With a 24-Week Open-Label Follow-Up to Evaluate the Effect of Avandia on Bone in Postmenopausal Women With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2017

At a glance

  • Drugs Rosiglitazone (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Oct 2012 Results assessing the effects of treatment on osteoclast activity presented at the 34th Annual Meeting of the American Society for Bone and Mineral Research.
    • 24 Mar 2012 Substudy assessing muscle mass and adiposity presented at the 2012 IOF World Congress on Osteoporosis and 11th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top